United Therapeutics (NASDAQ:UTHR) Reaches New 52-Week High After Analyst Upgrade

United Therapeutics Corporation (NASDAQ:UTHR) reached a new 52-week high during trading on Tuesday after HC Wainwright raised their price target on the stock from $600.00 to $660.00. HC Wainwright currently has a buy rating on the stock. United Therapeutics traded as high as $607.89 and last traded at $588.36, with a volume of 1721854 shares trading hands. The stock had previously closed at $522.83.

Several other brokerages have also issued reports on UTHR. Bank of America boosted their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday. Oppenheimer increased their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $486.00 to $575.00 and gave the stock an “equal weight” rating in a research note on Tuesday. TD Cowen boosted their price objective on shares of United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a research report on Monday. Finally, Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $586.00.

Insider Buying and Selling

In other United Therapeutics news, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $535.81, for a total value of $5,090,195.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at $21,707,270.53. This represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $529.95, for a total transaction of $4,398,585.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares of the company’s stock, valued at approximately $23,938,901.40. This trade represents a 15.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 333,820 shares of company stock valued at $165,495,478. 10.30% of the stock is owned by corporate insiders.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Phase 3 TETON‑1 results: Tyvaso met the trial’s key endpoint in idiopathic pulmonary fibrosis (IPF), driving a sharp runup in the stock because success expands Tyvaso’s addressable market beyond pulmonary arterial hypertension. United Therapeutics (UTHR) Is Up 11.5% After Positive IPF Phase 3 Tyvaso Data Met Key Endpoint
• Positive Sentiment: Company press release and institutional coverage reinforced the data readout, giving investors more confidence in a potential FDA filing and commercial upside for Tyvaso in IPF. United Therapeutics reports positive results for lung drug
• Positive Sentiment: Multiple analyst upgrades and price‑target increases (Bank of America, Wells Fargo, HC Wainwright, others) followed the TETON‑1 readout, amplifying buying pressure and pre‑market gaps. Higher targets highlight expected revenue expansion if IPF approval/commercialization succeeds. United Therapeutics Gets Dual Target Hikes From BofA and Wells Fargo
• Positive Sentiment: Sell‑side momentum: some firms (e.g., HC Wainwright) moved to Buy and raised targets materially, which supports further upside if clinical and regulatory paths stay on track. HC Wainwright raises UTHR price target to $660
• Neutral Sentiment: Valuation check: analysts and market write‑ups are reassessing UTHR’s valuation after the IPF data — positive clinical news boosts forward revenue expectations but raises near‑term valuation scrutiny. Investors should weigh upside against higher multiples. Assessing United Therapeutics (UTHR) Valuation After Positive Tyvaso Phase 3 IPF Trial Results
• Neutral Sentiment: Options flow and momentum trading: unusually high options activity and gap‑up headlines indicate speculative positioning that can amplify moves and volatility around catalysts (e.g., filings, guidance). United Therapeutics Target of Unusually High Options Trading (NASDAQ:UTHR)
• Neutral Sentiment: Sell‑side balance: some firms raised targets but left neutral/equal‑weight ratings, reflecting disagreement on upside vs. execution risk; that keeps upside concentrated in execution and regulatory milestones. Analysts Are Neutral on Top Healthcare Stocks: Gilead Sciences (GILD), United Therapeutics (UTHR)
• Negative Sentiment: Near‑term caution: some commentary flags valuation and execution risk plus mixed earnings‑estimate revision trends — these could limit further near‑term gains unless management provides clear regulatory/launch guidance. United Therapeutics (UTHR) Moves 12.5% Higher: Will This Strength Last?

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors have recently bought and sold shares of UTHR. Rockefeller Capital Management L.P. boosted its stake in shares of United Therapeutics by 10.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,323 shares of the biotechnology company’s stock worth $645,000 after acquiring an additional 127 shares during the period. Corient Private Wealth LLC grew its position in shares of United Therapeutics by 13.5% during the fourth quarter. Corient Private Wealth LLC now owns 19,248 shares of the biotechnology company’s stock worth $9,379,000 after purchasing an additional 2,289 shares in the last quarter. Rehmann Capital Advisory Group grew its position in shares of United Therapeutics by 9.8% during the fourth quarter. Rehmann Capital Advisory Group now owns 3,619 shares of the biotechnology company’s stock worth $1,767,000 after purchasing an additional 324 shares in the last quarter. Tobam raised its stake in United Therapeutics by 28.9% during the 4th quarter. Tobam now owns 9,857 shares of the biotechnology company’s stock valued at $4,803,000 after purchasing an additional 2,211 shares during the period. Finally, Wick Capital Partners LLC bought a new stake in United Therapeutics during the 4th quarter valued at approximately $297,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

The stock has a fifty day moving average of $502.93 and a 200 day moving average of $476.94. The company has a market capitalization of $24.99 billion, a PE ratio of 20.44, a PEG ratio of 1.72 and a beta of 0.75.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The business had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company’s revenue was up 7.4% on a year-over-year basis. During the same period last year, the firm posted $6.19 EPS. As a group, equities analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.